Author: José María Millán Salvador | Scientific Director of the Biomedical Research Network Center for Rare Diseases (CIBERER)
The European Union defines rare diseases (RDs), also known as orphan diseases or low-prevalence diseases, as life-threatening or chronically debilitating conditions with a prevalence of fewer than 5 cases per 10,000 inhabitants.
Although each rare disease affects a relatively small number of people, collectively they represent a major challenge to global public health. It is estimated that there are more than 7,000 such conditions, many of which are chronic, degenerative and life-threatening, with very limited and often ineffective therapeutic options. In Spain, RDs are estimated to affect 8% of the population, representing approximately 3 million people.
Rare disease research in Spain began in 1996 with the establishment of the Toxic Oil Syndrome Research Centre (CISAT) at the Carlos III Health Institute (ISCIII). In 1999, “The Action Programme on Rare Diseases” was published in the European Community (1295/1999/EC), and in 2001, CISAT was renamed CISATER, expanding its scope to include RDs alongside toxic oil syndrome. That same year, the Spanish-language Rare Disease Information Service (SIERE) was established, and RDs were included as a priority research area at the ISCIII.
In 2003, three networks focusing on RDs, REpIER, INERGEN and RECGEN, were established within the framework of the Thematic Networks for Cooperative Health Research (RETICS). In addition, CISATER was renamed the Rare Diseases Research Institute (IIER).
The success of collaborative research through the RETICS networks, particularly in the field of RDs due to the small number of patients, their geographical dispersion and the lack of available treatments, among other factors, led to the inclusion of the Rare Diseases Biomedical Research Network Centre (CIBERER) among the seven original centres established in 2006 as part of the Biomedical Research Networking Centres (CIBER). As a result, the research landscape in Spain has undergone a positive turning point, thanks to the development of these collaborative networks of excellence and major technological infrastructures.
Research into RDs is a race against time, characterised by numerous structural, economic and clinical obstacles.
What are the main challenges in rare disease research?
The path towards a cure or an accurate diagnosis for a rare disease is fraught with barriers inherent to the nature of these conditions:
1. The diagnostic odyssey and data fragmentation: One of the greatest challenges is the delay in obtaining an accurate diagnosis, which often takes years due to widespread gaps in clinical knowledge and the clinical and genetic heterogeneity inherent to RDs. As patients are widely dispersed geographically, clinical data often remain isolated across different healthcare centres, hindering large-scale research and the establishment of comprehensive registries documenting the prevalence and natural history of RDs.
The sequencing of the human genome in 2001 and the widespread use of high-throughput sequencing technology in 2005 revolutionised the diagnosis of RDs, as approximately 80% are estimated to have a genetic origin. Despite these advances, a very high proportion of patients still do not receive a diagnosis identifying the underlying genetic defect, with this proportion reaching up to 50% in some RDs.
2. Scarcity of samples and funding: As each individual condition affects only a small number of patients, traditional clinical trials are difficult to design. The degree of uncertainty is always considerably greater than for common diseases and, consequently, private investment tends to be low because there are no large, profitable pharmaceutical markets. Much of the responsibility therefore falls on public funding and the efforts of patient associations.
3. Lack of specific treatments: It is estimated that a very high proportion of patients with rare diseases lack a specific pharmacological treatment or therapy, limiting medical intervention to palliative or supportive care. In this context, advances in the field of advanced therapies, particularly gene therapy (bearing in mind the aforementioned 80%), are beginning to play a leading role and offer hope to healthcare professionals, researchers and patients with RDs. Another therapeutic approach focuses on drug repurposing, whereby medicines already approved for a particular common disease are used to treat a rare disease for which they have demonstrated efficacy. Compared with gene therapies, this strategy offers the advantage of a considerably simpler regulatory approval process.
The crucial role of structural advances in Spain
To address these major challenges, Spain’s scientific and healthcare systems have promoted pioneering initiatives that serve as international benchmarks.
CIBERER: Operating under the Carlos III Health Institute, CIBERER is an essential structure bringing together the country’s leading translational research groups. Its work focuses on bridging the gap between laboratory science and patient care, promoting integrated knowledge platforms and the development of collaborative projects that are indispensable for deciphering the genetic and molecular basis of these conditions. It has two Research Programmes that cut across the different RD research groups and aim to address the challenges outlined above: Omics Sciences and Computational Biology, and Therapy Discovery.
The IMPaCT-Genomics programme, which forms part of the Precision Medicine Infrastructure Associated with Science and Technology (IMPaCT) at the ISCIII and is coordinated by CIBERER itself, represents a milestone for public healthcare. IMPaCT-Genomics makes experimental omics analysis technologies and highly complex technologies available to undiagnosed patients throughout Spain, enabling highly complex cases to be resolved through advanced genetic testing and the coordinated reanalysis of data.
Another noteworthy initiative is the Únicas project. Jointly promoted by leading hospitals such as Sant Joan de Déu Hospital and patient federations, the Únicas project represents a revolutionary model of care and precision medicine. Its aim is to connect a network of hospitals across the country to ensure equitable access to complex treatments and diagnoses, combining clinical care, advanced telemedicine and cutting-edge research within a patient-centred environment for paediatric RDs.
Únicas seeks to eliminate the need for patients with RDs to travel from one location to another, ensuring instead that the data (clinical, genetic and imaging data) travel to enable a diagnosis.
Conclusion
Although the advances made throughout this century have been significant, much remains to be done. The challenges posed by rare diseases require us to move away from fragmentation and embrace collective intelligence, cutting-edge technology and geographical equity. Thanks to the synergy between integrated research centres such as CIBERER, collaborative healthcare networks such as Únicas and high-capacity national infrastructures such as IMPaCT, Spanish science is firmly positioned to transform the uncertainty faced by thousands of families into accurate diagnoses and genuine therapeutic hope. As recently as 23 October 2026, the Interterritorial Council of the Spanish National Health System approved the updated Rare Diseases Strategy of the Spanish National Health System, promoted by the Ministry of Health. This includes a cross-cutting research priority aimed at strengthening the basic and translational research that is so essential to overcoming these challenges.